17th January 2022
Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces that further to the announcement made on 14 December 2021 in respect of the conditional subscription to raise £1.65 million with Lanstead Capital Investors L.P., a circular to shareholders and a notice of general meeting has been sent to shareholders and is available on the Company’s website at: www.nuformix.com.
Download News